Premium
Imedeen® in the treatment of photoaged skin: an efficacy and safety trial over 12 months 1
Author(s) -
Kieffer Marianne Elholm,
Efsen Jan
Publication year - 1998
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1998.tb00765.x
Subject(s) - photoaging , medicine , transepidermal water loss , dermatology , melasma , hyperpigmentation , hypopigmentation , placebo , wrinkle , randomized controlled trial , surgery , pathology , stratum corneum , alternative medicine , gerontology
Background UV‐exposure induces photoaging of the skin. Objective Testing the efficacy and safety of oral Imedeen® in photoaged skin. Methods Three month placebo‐controlled randomized study of 144 subjects and 9‐month‐uncontrolled continuation. Efficacy measurements included clinical evaluation, self‐evaluation, photograph evaluation, as well as ultrasound, transepidermal water loss and replica measurements. Results After 3 months, no significant effects were detected. One years treatment gave significant improvement compared with baseline in investigator's evaluation of fine lines and overall photoaging, in photograph evaluation of fine lines, overall photoaging, telangiectasia and hyperpigmentation, in self‐evaluation of skin condition, density measurements by ultrasound, trans‐epidermal water loss and skin smoothness from analysis of skin replica. No serious side‐effects related to treatment were reported. Conclusion Imedeen® appears effective and safe for treatment of photoaged skin.